Name | Number of supported studies | Average coverage | |
---|---|---|---|
enterocyte | 7 studies | 29% ± 15% |
Insufficient scRNA-seq data for expression of SULT1A2 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
liver | 100% | 1485.44 | 226 / 226 | 63% | 2.13 | 254 / 406 |
lung | 100% | 517.93 | 577 / 578 | 26% | 0.56 | 297 / 1155 |
thymus | 100% | 643.28 | 652 / 653 | 24% | 0.51 | 145 / 605 |
kidney | 99% | 207.80 | 88 / 89 | 8% | 0.15 | 69 / 901 |
spleen | 100% | 332.06 | 241 / 241 | 0% | 0 | 0 / 0 |
pancreas | 94% | 100.73 | 309 / 328 | 4% | 0.15 | 8 / 178 |
brain | 92% | 140.74 | 2443 / 2642 | 0% | 0 | 0 / 705 |
adrenal gland | 90% | 193.71 | 231 / 258 | 1% | 0.02 | 3 / 230 |
ovary | 76% | 67.19 | 136 / 180 | 15% | 0.25 | 63 / 430 |
breast | 74% | 89.16 | 338 / 459 | 16% | 0.33 | 181 / 1118 |
stomach | 66% | 56.26 | 236 / 359 | 15% | 0.29 | 44 / 286 |
intestine | 71% | 594.23 | 689 / 966 | 8% | 0.13 | 41 / 527 |
bladder | 57% | 81.48 | 12 / 21 | 18% | 0.57 | 91 / 504 |
adipose | 75% | 105.23 | 900 / 1204 | 0% | 0 | 0 / 0 |
heart | 69% | 93.34 | 598 / 861 | 0% | 0 | 0 / 0 |
prostate | 61% | 53.93 | 150 / 245 | 1% | 0.02 | 5 / 502 |
peripheral blood | 56% | 84.39 | 522 / 929 | 0% | 0 | 0 / 0 |
esophagus | 38% | 29.28 | 553 / 1445 | 13% | 0.27 | 24 / 183 |
uterus | 36% | 26.24 | 62 / 170 | 6% | 0.12 | 27 / 459 |
blood vessel | 21% | 17.75 | 275 / 1335 | 0% | 0 | 0 / 0 |
skin | 10% | 6.29 | 185 / 1809 | 2% | 0.03 | 9 / 472 |
muscle | 11% | 5.85 | 87 / 803 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 2% | 0.03 | 1 / 45 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 80 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 29 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0018958 | Biological process | phenol-containing compound metabolic process |
GO_0006584 | Biological process | catecholamine metabolic process |
GO_0050427 | Biological process | 3'-phosphoadenosine 5'-phosphosulfate metabolic process |
GO_0009309 | Biological process | amine biosynthetic process |
GO_0006805 | Biological process | xenobiotic metabolic process |
GO_0006068 | Biological process | ethanol catabolic process |
GO_0051923 | Biological process | sulfation |
GO_0008202 | Biological process | steroid metabolic process |
GO_0005829 | Cellular component | cytosol |
GO_0005737 | Cellular component | cytoplasm |
GO_0008146 | Molecular function | sulfotransferase activity |
GO_0004062 | Molecular function | aryl sulfotransferase activity |
GO_0005515 | Molecular function | protein binding |
GO_0047894 | Molecular function | flavonol 3-sulfotransferase activity |
Gene name | SULT1A2 |
Protein name | Sulfotransferase (EC 2.8.2.-) Sulfotransferase 1A2 (ST1A2) (EC 2.8.2.1) (Aryl sulfotransferase 2) (Phenol sulfotransferase 2) (Phenol-sulfating phenol sulfotransferase 2) (P-PST 2) |
Synonyms | STP2 |
Description | FUNCTION: Sulfotransferase that utilizes 3'-phospho-5'-adenylyl sulfate (PAPS) as sulfonate donor to catalyze the sulfate conjugation of catecholamines, phenolic drugs and neurotransmitters. Is also responsible for the sulfonation and activation of minoxidil. Mediates the metabolic activation of carcinogenic N-hydroxyarylamines to DNA binding products and could so participate as modulating factor of cancer risk. |
Accessions | E9PM76 E9PKW4 ENST00000395630.5 P50226 ENST00000526384.1 ENST00000534108.5 ENST00000533150.5 ENST00000335715.9 E9PKR8 |